본문 바로가기

기관정보

기관정보 기관정보상세

기관상세정보

학회일반현황
학회일반현황
학회명 국문 대한신경정신의학회 기관구분 학회
영문 Korean Neuropsychiatric Association 제재이력 변경이력
전화번호   팩스번호  
홈페이지 http://www.knpa.or.kr/ 이메일  
주소 [137070] 서울 서초구 서초동 1685-8 G-five Central Plaza 522호
대표자 성명 권준수
소속 서울대학교 직위 교수
임기 2018-01-01 ~ 2019-12-31
실무자 성명 임다슬 연락처(핸드폰)
기업단체구분
연구분야 정신과학
행정인력수 3명 전임연구인력수 0명
설립구분 기타 설립일자 1945-09-07
설립목적
											대한신경정신의학회는 1945년 9월 7일 조선 정신신경학회로 창립되어  초대회장에 심호섭박사, 부회장에 명주완박사가 추천되었고, 10년후인 1955년 6월 4일 학회 명칭을 대한신경정신의학회로 개칭하였으며 명주완박사가 회장으로 추천되어 그 후 현재까지 정신건강에 대한 학문적 발전과 국민  건강에 이바지하여 오고 있다. 구체적인 본 기관의 설립목적은 다음과 같다.

  1. 신경정신의학의 발전 및 정신건강에 관한 연구, 학술, 교육에 관한 사업
  2. 국민의 정신건강 증진을 위한 사업
  3. 회원상호간의 친목도모와 회원의 권익신장에 관한 사업
  4. 관련단체 또는 관련기관과의 협조에 관한 사업
  5. 기타 본회의 목적달성에 필요한 사업

										
연구윤리제정일 2005-01-01 원문서비스url https://jknpa.org/
연구윤리내용
										Psychiatry Investigation Ethics Policies 

Human and Animal Research
Competing Interests
Prior Publication
Reviewer and Editor Exclusions
Scientific and Editorial Misconduct
Reporting Guidelines for Specific Study Designs
Publication of Studies Sponsored by Pharmaceutical Companies
Embargoes and the Media


1. Human and Animal Research

All research involving humans and animals must have been approved by the authors' institutional review board or equivalent committee, and that board must be named by the authors. In the case of human participants, informed consent must have been obtained, and all clinical investigation must have been conducted according to the principles expressed in the Declaration of Helsinki. Authors should submit a statement from the ethics committee or institutional review board indicating approval of the research. We also encourage authors to submit a sample of a patient consent form, and may require submission on particular occasions.

2. Competing Interests

Authors are asked at submission to declare whether they have any financial, personal, or professional interests that could be construed to have influenced their paper. Reviewers are also asked to declare any interests that might interfere with their objective assessment of a manuscript. Any relevant competing interests of authors must be available to editors and reviewers during the review process and will be stated in published articles. 

3. Prior Publication

When submitting an article, all authors are asked to indicate that they have not submitted a similar manuscript for publication elsewhere. If related work has been submitted elsewhere, then a copy must be included with the article submitted to Psychiatry Invest. Reviewers will be asked to comment on the overlap between related submissions.

4. Reviewer and Editor Exclusions

Upon submission of a manuscript, authors are asked if they wish to exclude any specific academic editors or reviewers from the peer review of their article. The editorial team will respect these requests so long as this does not interfere with the objective and thorough assessment of the article. See the relevant guidelines for reviewers.
 
5. Scientific and Editorial Misconduct

Scientific misconduct is defined as "fabrication, falsification, plagiarism, or other practices that seriously deviate from those that are commonly accepted within the academic community for proposing, conducting, or reporting research." In cases where there is a suspicion or allegation of scientific misconduct or fraudulent research in manuscripts submitted for review, Psychiatry Invest reserves the right to pass along these manuscripts to the sponsoring or funding institution or other appropriate authority for investigation. Although Psychiatry Invest recognizes its responsibility toensure that the suspicion of misconduct has been addressed, we do not ourselves make such determinations. The Psychiatry Invest is a member of the Korean Association of Medical Journal Editors (KAMJE). Cases of research or publication misconduct may also be referred to KAMJE in an anonymised format.

6. Reporting Guidelines for Specific Study Designs

a. Clinical Trials
Authors must submit original protocols as supporting information to allow editors and reviewers to assess manuscripts fully. Any deviation from the protocol must be explained.
We require that authors of clinical trials adhere to the CONSORT reporting guidelines appropriate to their trial design. Please check the CONSORT statement Web site (http://www.consort-statement.org/) for information on the appropriate guidelines for specific trial types. All reports of the results of randomized clinical trials should include the CONSORT flow diagram as Figure 1, and authors should complete and submit the checklist contained within the CONSORT statement. Information on statistical methods or participants beyond what is indicated in the CONSORT statement should be reported according to the specifications indicated in the Methods section under Preparation of Manuscripts.
Psychiatry Invest supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration. All trials initiated after 1 July 2005 must be registered prospectively in a publicly accessible registry (i.e., before patient recruitment has begun), or they will not be considered for publication. For trials initiated before 1 July 2005, all trials must be registered before submission to our journals. The trial's registration number must be provided at the time of submission. 

b. Systematic Reviews and Meta-Analyses of Randomized Controlled Trials
Reports of meta-analyses of randomized controlled studies should use the QUOROM statement as a guide (Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF [1999] Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement. Lancet 354: 1896900), and should include a copy of the QUOROM checklist. 

c. Epidemiological Studies
For reports of epidemiological studies, you should consult the STROBE initiative (http://www.strobe-statement.org/). 

d. Microarray Experiments
Reports of microarray experiments should conform to the MIAME guideline (http://www.mged.org/Workgroups/MIAME/miame.html) and the data from the experiments must be deposited in a publicly accessible database.

7. Publication of Studies Sponsored by Pharmaceutical Companies.

We support the development of guidelines for the reporting of studies sponsored by pharmaceutical companies (Current Medical Research and Opinion, 2003). 

8. Embargoes and the Media

Authors are of course at liberty to present their findings at medical or scientific conferences ahead of publication. We recommend, however, that authors not contact the media or respond to such contact unless an article has been accepted for publication and an embargo date has been established. Respect for press embargoes will help to ensure that your work is reported accurately in the popular media. If a journalist has covered a piece of work ahead of publication, this will not affect consideration of the work for publication.

										
연구윤리파일   

LoadingLoading....